That report is incredibly confused in its discussion of competitors to 68GA-PSMA11 (Illucix)
In their consideration of the comparison of 68GA-PSMA11 to 18F-DCFPyL they conclude they are about the same in terms of diagnostic value but they then go on to cite a paper that compared 68Ga-PSMA to 18F-Fluciclovine that reached the conclusion that 68Ga-PSMA was superior.
The problem is that 18F-Fluciclovine is an older class of tracer nothing like 18F-DCFPyL and is no way a serious competitor to Illucix. To make the report harder to read they don't refer to 18F-Fluciclovine by name instead they just call it 18F PET CT which is a fairly meaningless term which could confusingly also include 18F-DCFPyL.
I can't decide if they were simply out of their depth or were deliberately trying to downplay competition.
- Forums
- ASX - By Stock
- TLX
- Is a $2,131,889,198.56 market cap justified
Is a $2,131,889,198.56 market cap justified, page-26
-
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$18.61 |
Change
0.130(0.70%) |
Mkt cap ! $6.227B |
Open | High | Low | Value | Volume |
$18.69 | $18.80 | $18.37 | $19.72M | 1.061M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 161 | $18.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.62 | 450 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 26 | 18.450 |
1 | 108 | 18.430 |
1 | 163 | 18.350 |
1 | 5000 | 18.310 |
3 | 6163 | 18.300 |
Price($) | Vol. | No. |
---|---|---|
18.620 | 450 | 1 |
18.700 | 400 | 1 |
18.900 | 1500 | 1 |
19.010 | 3200 | 2 |
19.050 | 512 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online